Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the administration of beta-lactam antibiotics in extended infusion in hematological patients with febrile neutropenia after 5 days of treatment. The beta-lactam antibiotics analyzed are the following: piperacillin-tazobactam, cefepime and meropenem. Half of patients will receive the antibiotic in intermittent infusion, while the other half will receive it in extended infusion.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitari de Bellvitge
• Collaborators: Institut d'Investigació Biomèdica de Bellvitge; Instituto de Salud Carlos III
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; beta-Lactams; Cefepime; Lactams; Meropenem; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam

Criteria

Inclusion Criteria:

1. Adult patients (age ≥18 years) of both sexes.

2. Patients admitted in Hematological wards.

3. With any of the following diagnoses:

1. Acute leukemia receiving chemotherapy.

2. Autologous or allogeneic hematopoietic stem cell transplant recipients.

4. With an episode of febrile neutropenia: ≥ 38.0ºC and <500 neutrophils/mm3 or <1000 with a predicted decrease within 24-48 hours.

5. Patient requiring treatment with a beta-lactam antibiotic: cefepime, piperacillin /tazobactam or meropenem, in monotherapy or in combination with another antibiotic.

6. Written informed consent has been obtained from the patient or their legal representative grants.

Exclusion Criteria:

1. Allergy to study drugs.

2. Patient receiving systemic antibiotic treatment (except for prophylaxis) at the time of onset of febrile neutropenia.

3. Absence of fever.

4. Patients with epilepsy.

5. Severe renal impairment (defined as creatinine clearance <30 mL / min)

6. Previously enrolled patients in whom the time between the inclusion and the current episode is less than 5 weeks.

7. Previously enrolled patients without current resolution of the first episode.